# A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.

> **NCT02040584** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 217 (actual)

## Conditions studied

- Liver Transplant

## Interventions

- **DRUG:** Minimisation of TAC
- **DRUG:** TAC + MMF + corticosteroids

## Key facts

- **NCT ID:** NCT02040584
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-20
- **Primary completion:** 2016-02-10
- **Final completion:** 2016-02-10
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2019-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02040584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02040584, "A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02040584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*